The dopamine receptor subtype in brain is DRD1. This receptor modulates several cellular functions and its expression has been studied in detail concerning extracellular signaling. A publication [1] indicates that there is also miRNA regulation (suppression) of DRD1 transcription and translation due to miR-142-3p interaction with the DRD1 3'-untranslated region (1, 277 DARPP-32 is also known as Protein phosphatase 1, regulatory (inhibitor) subunit 1B (PPP1R1B). This protein as well as DRD1 is expressed in medium spiny neurons and DARPP-32 is crucial in a number of pathways relating to drug abuse and neuropsychiatric disease. Discovery of DARPP-32 lead to the award of the Nobel Prize to Dr. P. Greengard (Rockefeller University, NY, NY) [3].
Dopamine participates in reward and function in the brain and dopamine pathway dysfunction is involved in drug abuse (e.g. cocaine, amphetamine, nicotine, caffeine, LSD, PCP, ethanol morphine, alcoholism, and smoking), gambling, novelty seeking, and additional neuropsychiatric diseases including schizophrenia, attention-deficit/hyperactivity disorder, Huntington's disease, and Parkinson's disease. Dopamine transporter (SLC6A3) is a participant as well. Signaling pathways interconnect DARPP-32 and dopamine pathways. The kinase, CK2 is also implicated among these pathways [3-5].
It is left as a puzzle for the interested reader to identify the various genes and their functions in the (Figures 1 & 2) [2, 6, 7] .
Thus, the continued study of DARPP-32 and related pathways may lead to cures for the many pathologies stemming from diseases as mentioned above. 
